PDF(Sci-hub)
Abstract：
Use of triptans for acute treatment of migraine is associated with insufficient efficacy and/or tolerability in approximately 30-40% of people. We conducted a systematic literature review (SLR) to synthesize definitions, terminology, subsequent treatment outcomes, and characteristics associated with this subpopulation.
A comprehensive SLR was conducted to identify studies, published from Jan 1995 to May 2019, which focused on insufficient efficacy and/or tolerability to triptans.
Thirty-five publications were identified, of which 22 described randomized controlled trials and open-label studies, and 13 described observational studies. Across studies, multiple objectives and a high amount of variability in methodologies and outcomes were noted. The most commonly applied measures of efficacy were headache pain freedom and pain relief at 2 h. Ten studies assessed efficacy of switching or optimizing treatment in patients with historical insufficient efficacy or tolerability to previous triptan treatment and demonstrated varying levels of success. Factors associated with increased risk of triptan insufficient efficacy included severe baseline headache severity, photophobia, phonophobia, nausea, and depression.
Irrespective of the methodology or definition used to identify people with insufficient efficacy and/or tolerability to triptans, study results support the assertion that a high unmet need remains for effective acute treatment of migraine.
A comprehensive SLR was conducted to identify studies, published from Jan 1995 to May 2019, which focused on insufficient efficacy and/or tolerability to triptans.
Thirty-five publications were identified, of which 22 described randomized controlled trials and open-label studies, and 13 described observational studies. Across studies, multiple objectives and a high amount of variability in methodologies and outcomes were noted. The most commonly applied measures of efficacy were headache pain freedom and pain relief at 2 h. Ten studies assessed efficacy of switching or optimizing treatment in patients with historical insufficient efficacy or tolerability to previous triptan treatment and demonstrated varying levels of success. Factors associated with increased risk of triptan insufficient efficacy included severe baseline headache severity, photophobia, phonophobia, nausea, and depression.
Irrespective of the methodology or definition used to identify people with insufficient efficacy and/or tolerability to triptans, study results support the assertion that a high unmet need remains for effective acute treatment of migraine.
摘要：
使用曲坦用于偏头痛的急性治疗在大约30-40%的人中与不足的功效和/或耐受性相关。我们进行了系统的文献综述(SLR)来综合定义，术语,后续治疗结果，以及与该亚群相关的特征。
进行了全面的SLR以确定研究，发表于1995年1月至2019年5月，重点关注曲坦的疗效和/或耐受性不足。
确定了35种出版物，其中22项描述了随机对照试验和开放标签研究，和13描述了观察性研究。在整个研究中，研究人员注意到多个目标以及方法和结果的高度可变性.最常用的疗效指标是2h时的头痛缓解和疼痛缓解。十项研究评估了历史上疗效不足或对先前曲坦治疗耐受性不足的患者的转换或优化治疗的疗效，并证明了不同程度的成功。与曲坦疗效不足风险增加相关的因素包括严重的基线头痛严重程度，畏光,恐惧症,恶心,和抑郁症。
无论用于识别对曲坦类药物疗效和/或耐受性不足的人的方法或定义如何，研究结果支持了对偏头痛的有效急性治疗仍有很高的未满足需求的断言.
进行了全面的SLR以确定研究，发表于1995年1月至2019年5月，重点关注曲坦的疗效和/或耐受性不足。
确定了35种出版物，其中22项描述了随机对照试验和开放标签研究，和13描述了观察性研究。在整个研究中，研究人员注意到多个目标以及方法和结果的高度可变性.最常用的疗效指标是2h时的头痛缓解和疼痛缓解。十项研究评估了历史上疗效不足或对先前曲坦治疗耐受性不足的患者的转换或优化治疗的疗效，并证明了不同程度的成功。与曲坦疗效不足风险增加相关的因素包括严重的基线头痛严重程度，畏光,恐惧症,恶心,和抑郁症。
无论用于识别对曲坦类药物疗效和/或耐受性不足的人的方法或定义如何，研究结果支持了对偏头痛的有效急性治疗仍有很高的未满足需求的断言.
